non-small cell lung cancer

Showing 15 posts of 40 posts found.

Keytruda image

MSD’s Keytruda impresses in lung cancer chemotherapy trial

December 21, 2015
Manufacturing and Production, Research and Development MSD, PD-L1, docetaxel, keytruda, lung cancer, non small cell lung cancer, non-small cell lung cancer, pd-1, pembrolizumab

MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial …

NHS sign

NICE rejects BMS cancer drug in draft guidance

December 16, 2015
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …

Chest x ray

Roche lung cancer drug Alecensa gets rapid US approval

December 14, 2015
Sales and Marketing Alecensa, FDA, Genentech, Roche, accelerated approval, alectinib, lung cancer, non-small cell lung cancer

The US health watchdog has approved Alecensa, a drug for people with certain types of non-small cell lung cancer manufactured …

MHRA

Early UK access for AstraZeneca lung cancer drug

December 9, 2015
AstraZeneca, Early Access to Medicines Scheme, Tagrissa, eams, lung cancer, non small cell lung cancer, non-small cell lung cancer, osimertinib

UK patients will be among the first in Europe to have free access to AstraZeneca’s cancer drug osimertinib, after the …

Xalkori

Pfizer lung cancer treatment gets expanded EU approval

December 1, 2015
Research and Development, Sales and Marketing NSCLC, Pfizer, Xalkori, crizotinib, lung cancer, non-small cell lung cancer

Pfizer UK has received European Commission approval for a label update to expand use of Xalkori (crizotinib) to first-line treatment …

Chest x ray

Lilly cancer drug gets US approval

November 26, 2015
NSCLC, Portrazza, lilly, lung cancer, necitumumab, non-small cell lung cancer, oncology

Eli Lilly has received FDA approval for its monoclonal antibody Portrazza, in combination with gemcitabine and cisplatin, for patients with …

nsclc_merck_pfizer

Merck and Pfizer begin new Phase III avelumab trial in lung cancer

November 5, 2015
Medical Communications, Research and Development Merck, Pfizer, avelumab, lung cancer, non-small cell lung cancer

Merck and Pfizer have commenced an international Phase III study of the investigational cancer immunotherapy avelumab in patients with non-small …

AstraZeneca halts lung cancer trials amidst safety concerns

October 13, 2015
Manufacturing and Production AZD9291, AstraZeneca, MEDI4736, NSCLC, drug safety, durvalumab, interstitial lung disease, lung cancer, non-small cell lung cancer

AstraZeneca is stopping two trials of a combination of two of its pipeline cancer treatments, after reports that the pairing …

Chest x ray

Roche lung cancer therapy succeeds in mid-stage trial

August 17, 2015
Research and Development, Sales and Marketing Genentech, Roche, atezolizumab, lung cancer, non-small cell lung cancer

Roche’s biotech arm Genentech has scored positive results in a pivotal Phase II study of its investigational cancer immunotherapy atezolizumab. …

Opdivo

Bristol-Myers Squibb launches Opdivo in the UK for lung cancer

August 12, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, NSCLC, immunotherapy, lung cancer, non small cell lung cancer, non-small cell lung cancer, opdivo

The immuno-oncology drug Opdivo is available in the UK for people with lung cancer, after Bristol-Myers Squibb launched the drug …

AstraZeneca

AstraZeneca receives US approval for Iressa

July 16, 2015
Medical Communications, Sales and Marketing AstraZeneca, FDA, Iressa, lung cancer, non-small cell lung cancer

AstraZeneca’s lung cancer therapy Iressa has been approved by the FDA – four years after the company pulled it from the …

Opdivo

BMS’ Opdivo improves lung cancer survival

May 29, 2015
Research and Development, Sales and Marketing ASCO, BMS, Bristol-Myers Squibb, NSCLC, lung cancer, nivolumab, non-small cell lung cancer, opdivo

A Phase III trial of Bristol-Myers Squibb’s immunotherapy Opdivo has found it increases overall survival in people with a common …

astrazeneca image

FDA grants AstraZeneca immune drug orphan status

April 15, 2015
Sales and Marketing AstraZeneca, FDA, Iressa, MEDI4736, MedImmune, NSCLC, US, gefitinib, non-small cell lung cancer, tremelimumab

The US Food and Drug Administration has granted orphan drug designation to AstraZeneca’s anti-CTLA-4 monoclonal antibody tremelimumab for the treatment …

The Gateway to Local Adoption Series

Latest content